Ultragenyx is moving from a broad drug pipeline to concentrate on rare diseases, supported by four approved products and several late-stage candidates. Despite a recent Phase 3 trial failure and expected net loss in early 2026, the company maintains its revenue forecast of $730–$760 million for 2026, backed by a scalable commercial model and cost management. Upcoming catalysts include FDA review decisions for DTX401 and UX111 in the second half of 2026 and pivotal Phase 3 data for GTX-102 targeting Angelman syndrome. Successful execution on these fronts could transform Ultragenyx from a cash-consuming research company into a profitable rare disease platform.
MicroStrategy's executive chairman Michael Saylor signaled another Bitcoin purchase even as the company faces challenges with its STRC perpetual preferred stock, which recently dropped below $89. This decline has increased the company's dividend cost...
Micron Technology has seen its stock surge 830% in the past year due to soaring demand for AI-related high-bandwidth memory and rising prices amid tight supply. Despite analysts expecting extraordinary fiscal Q3 results with massive revenue and earni...
Meta Platforms' stock is currently trading at $567.58, significantly below its 24/7 Wall St. price target of $837.78, implying a 47.61% upside. Despite a recent selloff due to increased capital expenditure guidance for 2026, Meta reported strong Q1 e...
Okeanis Eco Tankers reported exceptional Q1 results with net income rising 601% year-over-year, driven by explosive spot rates and fleet expansion. The company's young, scrubber-fitted fleet and strong owner alignment have supported its outperformanc...
TPG Mortgage Investment Trust (MITT) is rated a speculative Buy, offering a high 12% dividend yield while trading at a 20% discount to its book value. The dividend payout ratio is high at 96.74%, indicating a narrow margin of safety and elevated risk...
